SAN DIEGO, Feb. 6, 2018 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that
that members of its senior management team will present at two
upcoming investor conferences in New York
City.
- LEERINK Partners 7th Annual Global Healthcare
Conference - Presenting on Thursday,
February 15, at 9:30 a.m.
EST.
- RBC Capital Markets Global Healthcare Conference - Presenting
on Wednesday, February 21, at
3:35 p.m. EST.
A live audio webcast of the presentations will be available
under the investor relations section of Arena's website at
www.arenapharm.com. A replay of the presentation will be available
for 30 days following the event.
To learn more about Arena's clinical programs, development plans
and upcoming milestones for 2018, a video interview with CEO
Amit Munshi is available under the
Events and Presentations section of Arena's website at
www.arenapharm.com.
About Arena Pharmaceuticals
Arena Pharmaceuticals is
focused on developing novel, small molecule drugs with optimized
receptor pharmacology and pharmacokinetics designed to deliver
broad clinical utility across several therapeutic areas. Arena's
proprietary pipeline includes potentially first- or best-in-class
programs. The most advanced investigational clinical programs
are ralinepag (APD811), which will be commencing a Phase 3 program
for pulmonary arterial hypertension (PAH), and etrasimod (APD334),
which is in Phase 2 for a broad range of immune and inflammatory
conditions. Arena is also evaluating APD371 in Phase 2 for
the treatment of pain associated with Crohn's disease. In addition,
Arena has collaborations with the following pharmaceutical
companies: Everest Medicines Limited (ralinepag and etrasimod in
Greater China and select Asian
countries), Axovant Sciences GmbH (nelotanserin - Phase 2),
Boehringer Ingelheim International GmbH (undisclosed target -
preclinical), and Eisai Co., Ltd. and Eisai Inc.
(BELVIQ® - marketed product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These forward-looking statements may be
accompanied by words such as "will," "upcoming," "focused on,"
"designed to," "potentially," "may," or words of similar meaning,
or by the fact that they do not relate strictly to historical or
current facts. Such forward-looking statements include statements
about the upcoming presentations and about Arena's focus, programs
and collaborations. For such statements, Arena claims the
protection of the Private Securities Litigation Reform Act of 1995.
Actual events or results may differ materially from Arena's
expectations. Factors that could cause actual results to differ
materially from the forward-looking statements include that
clinical programs may not proceed at the time or in the manner
expected or at all, as well as those factors disclosed in Arena's
filings with the Securities and Exchange Commission. These
forward-looking statements represent Arena's judgment as of the
time of this release. Arena disclaims any intent or obligation to
update these forward-looking statements, other than as may be
required under applicable law.
Corporate Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original
content:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-upcoming-investor-conferences-300594579.html
SOURCE Arena Pharmaceuticals, Inc.